Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
Celularity Inc. filed a current report dated May 21, 2024, concerning its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024. The filing was signed on May 24, 2024.
Financial Metrics and Liquidity
This Form 8-K does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating or financial metrics. The company stated that preparation of its March 31, 2024 financial statements remained incomplete because of delays in filing its 2023 Form 10-K.
Material Changes Versus the Prior Comparable Period
- Celularity did not file its Q1 2024 Form 10-Q by the extended deadline provided under Rule 12b-25, which expired on May 20, 2024.
- The company also remained delinquent in filing its 2023 Form 10-K, as previously reported on April 22, 2024.
- On May 21, 2024, Nasdaq notified Celularity that it was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports.
Outlook, Risks, Contingencies, and Unusual Items
- Celularity must submit a compliance plan to Nasdaq no later than June 17, 2024.
- If Nasdaq accepts the plan, the company may have until October 14, 2024, to regain compliance.
- The Nasdaq notice had no immediate effect on the listing or trading of Celularity’s Class A common stock or warrants, which continued to trade under CELU and CELUW.
- Celularity intends to submit the required plan and evaluate available compliance options.
- There is no assurance that Nasdaq will accept the plan, that Celularity will regain compliance within the permitted period, or that it will satisfy other Nasdaq listing requirements.
Key Facts for Investors to Verify
- Whether Celularity filed its 2023 Form 10-K and Q1 2024 Form 10-Q.
- Whether Nasdaq accepted the company’s compliance plan submitted by June 17, 2024.
- Whether the company regained compliance by the applicable deadline, potentially October 14, 2024.
- Whether any subsequent Nasdaq action affected the continued listing of CELU or CELUW.
- The financial results, liquidity position, and material disclosures in the delayed 2023 Form 10-K and Q1 2024 Form 10-Q.